Harold Keer
Corporate Officer/Principal bei Stanford University
Aktive Positionen von Harold Keer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Stanford University | Corporate Officer/Principal | - | - |
Karriereverlauf von Harold Keer
Ehemalige bekannte Positionen von Harold Keer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EXELIXIS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.07.2011 | - |
Corporate Officer/Principal | - | 06.07.2011 | |
TITAN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
FIVE PRIME THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.07.2011 | - |
Corporate Officer/Principal | - | 06.07.2011 |
Ausbildung von Harold Keer
Northwestern University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
EXELIXIS, INC. | Health Technology |
TITAN PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Börse
- Insiders
- Harold Keer
- Erfahrung